Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05891366 · ClinicalTrials.gov registry record · Phase 1
Single Ascending Dose Study of WAL0921 in Healthy Subjects
A Phase 1 study, sponsored by Walden Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT05891366 is a Phase 1 study that has completed, run by Walden Biosciences. The registered enrollment target is 40 participants.
The verdict
NCT05891366, a Phase 1 study, has completed, sponsored by Walden Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, pharmacokinetics, and pharmacodynamics of WAL0921 in healthy subjects.
Interventions
- DRUG Placebo
- DRUG WAL0921
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2023-05-31 |
| Est. Completion | 2024-01-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05891366
The ClinicalTrials.gov registry entry for NCT05891366 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Walden Biosciences, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05891366 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05891366 about?
NCT05891366 is a clinical study titled "Single Ascending Dose Study of WAL0921 in Healthy Subjects". This is a randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, pharmacokinetics, and pharmacodynamics of WAL0921 in healthy subjects.
What is the current status of trial NCT05891366?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2023-05-31. Estimated completion is 2024-01-09.
What interventions are being tested in trial NCT05891366?
The interventions under investigation include: Placebo (DRUG), WAL0921 (DRUG).
Who is sponsoring clinical trial NCT05891366?
This trial is sponsored by Walden Biosciences, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.